Patents by Inventor Ashley Ian Bush

Ashley Ian Bush has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180284141
    Abstract: The present invention relates to methods for predicting a risk of cognitive deterioration, monitoring progression of cognitive deterioration and diagnosing cognitive deterioration in a patient. The present invention further relates to methods for diminishing progression rate of cognitive deterioration in a patient by lowering brain iron levels in the patient or lowering CSF ferritin levels in the patient.
    Type: Application
    Filed: April 1, 2016
    Publication date: October 4, 2018
    Applicant: CRC For Mental Health Ltd
    Inventors: Scott Ayton, Noel Faux, Ashley Ian Bush
  • Patent number: 7653428
    Abstract: The invention provides a method of diagnosing, prognosing, staging, and/or monitoring a mammalian amyloidogenic disorder or a predisposition thereto by detecting a protein or polypeptide aggregate in the cortical and/or supranuclear regions of an ocular lens of the mammal.
    Type: Grant
    Filed: August 28, 2006
    Date of Patent: January 26, 2010
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Lee E. Goldstein, Leo T. Chylack, Jr., Ashley Ian Bush
  • Patent number: 7107092
    Abstract: A method of diagnosing, prognosing, staging, and/or monitoring a mammalian amyloidogenic disorder or a predisposition thereto by detecting a protein or polypeptide aggregate in the cortical and/or supranuclear regions of an ocular lens of the mammal.
    Type: Grant
    Filed: August 21, 2001
    Date of Patent: September 12, 2006
    Assignees: The General Hospital Corporation, The Brigham and Women's Hospital, Inc.
    Inventors: Lee E. Goldstein, Leo T. Chylack, Jr., Ashley Ian Bush
  • Publication number: 20040265847
    Abstract: The present invention is directed to methods for treating Alzheimer's Disease by modulating divalent cation, trivalent cation and/or heparin interaction with amyloid precursor protein (APP). In particular, the present invention is directed to methods for treating Alzheimer's Disease by administering to a patient with Alzheimer's Disease a therapeutically effective amount of a zinc binding agent for modulating the interaction of zinc and/or heparin with APP and thereby preventing the aberrant processing of APP.
    Type: Application
    Filed: November 19, 2003
    Publication date: December 30, 2004
    Inventors: Colin Louis Masters, Ashley Ian Bush, Konrad Traugott Beyreuther
  • Publication number: 20020091321
    Abstract: The invention provides a method of diagnosing, prognosing, staging, and/or monitoring a mammalian amyloidogenic disorder or a predisposition thereto by detecting a protein or polypeptide aggregate in the cortical and/or supranuclear regions of an ocular lens of the mammal.
    Type: Application
    Filed: August 21, 2001
    Publication date: July 11, 2002
    Inventors: Lee E. Goldstein, Leo T. Chylack, Ashley Ian Bush
  • Patent number: 5705401
    Abstract: The present invention relates to a method of assaying for Alzheimer's disease in a human by determining the relative abundance of one or more forms of amyloid precursor protein (APP) or the enzyme responsible for said forms in circulatory fluid and to a method for treating the disease by modulating divalent cation, trivalent cation and/or heparin interaction with APP.
    Type: Grant
    Filed: September 16, 1994
    Date of Patent: January 6, 1998
    Assignee: The University of Melbourne
    Inventors: Colin Louis Masters, Ashley Ian Bush, Konrad Traugott Beyreuther